Compare BridgeBio Pharma Inc (BBIO) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Otis Worldwide Corp — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Otis Worldwide Corp trades at $73.45 (market cap $27.74B). The key difference: Otis Worldwide Corp is the larger of the two by market cap, and Otis Worldwide Corp pays a 2.42% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | OTIS | |
|---|---|---|
Market Cap | $16.61B | $27.74B |
Sector | Health | Industrials |
52-Week High | $90.17 | $93.62 |
52-Week Low | $47.29 | $69.34 |
Enterprise Value | $18.16B | $35.77B |
Dividend Yield | — | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Otis Worldwide (OTIS) trades at $73.99, up 0.22% with a bullish technical signal. The company maintains stable revenue around $14.4B but faces margin pressure despite strong service segment growth. Recent Q2 2026 earnings beat estimates but included guidance cuts, reflecting ongoing challenges in new equipment demand. Analyst consensus remains divided with a $92.50 price target suggesting 25% upside potential.
The investment case hinges on service segment momentum offsetting equipment weakness, but margin compression and elevated debt levels pose risks. With mixed analyst ratings and recent institutional selling, the stock offers value if service margins improve, though execution risks remain elevated in the current economic environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
